Keros director sells 551 shares at $10.30 avg

Q: What insider transaction did KROS director Charles W. Newton report?

Charles W. Newton reported a sale of 551 shares of Keros Therapeutics, Inc. common stock on August 18, 2026, in a transaction coded as a sale in an open market or private transaction.

Q: At what price did the KROS insider shares sell?

The reported weighted average sale price was $10.30 per share. The filing states the shares were sold in multiple transactions at prices ranging from $10.16 to $10.49 per share, inclusive.

Q: How many KROS shares does Charles W. Newton own after this transaction?

After the reported sale, Charles W. Newton directly holds 12,114 shares of Keros Therapeutics, Inc. common stock, according to the Form 4.

Q: How many KROS shares did the insider sell in total in this filing?

The Form 4 reports that Charles W. Newton sold 551 shares of Keros Therapeutics, Inc. common stock in this transaction, with no additional purchases or derivative exercises reported.

Keros Therapeutics, Inc. (KROS) director Charles W. Newton reported selling 551 shares of common stock on August 18, 2026 in a transaction coded as an open market or private sale.

Filing Impact

(Neutral)

Filing Sentiment

(Neutral)

Form Type

Rhea-AI Filing Summary

Keros Therapeutics, Inc. (KROS) director Charles W. Newton reported selling 551 shares of common stock on August 18, 2026 in a transaction coded as an open market or private sale. The weighted average sale price was $10.30 per share, with individual trades between $10.16 and $10.49. After this sale, he directly holds 12,114 shares. The sale was made pursuant to a Rule 10b5-1 trading plan adopted on March 12, 2026.

Insider Trade Summary 10b5-1

Net Seller: 551 shares

Net Sell 1 txn

Insider Newton Charles W.

Role Director

Sold 551 shs ($6K)

Type	Security	Shares	Price	Value
Sale	Common Stock ^{F1, F2}	551	$10.30	$6K

Holdings After Transaction: Common Stock — 12,114 shares (Direct)

Footnotes (2)

F1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.
F2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Key Figures

Shares sold: 551 shares Weighted average sale price: $10.30 per share Sale price range: $10.16 to $10.49 per share +2 more

5 metrics

Shares sold 551 shares Common stock sale on August 18, 2026

Weighted average sale price $10.30 per share Reported for the 551-share sale

Sale price range $10.16 to $10.49 per share Range of prices for multiple sale transactions

Shares owned after transaction 12,114 shares Direct holdings following the reported sale

Rule 10b5-1 plan adoption date March 12, 2026 Trading plan under which the sale was executed

Key Terms

Rule 10b5-1 trading plan, weighted average price, open market or private transaction

3 terms

Rule 10b5-1 trading plan regulatory

"The transactions were pursuant to a Rule 10b5-1 trading plan adopted"

A Rule 10b5-1 trading plan is a pre-arranged schedule that allows company insiders to buy or sell stock at specific times, even if they have inside information. It helps prevent accusations of unfair trading by making these transactions look planned and transparent, rather than sneaky or illegal.

weighted average price financial

"The price reported in Column 4 is a weighted average price."

Weighted average price is the average price of a security where each trade or component is counted according to its size, so bigger trades pull the average more than smaller ones. Think of it like calculating the average cost of a grocery haul where items you bought more of have greater influence on the final per-item cost. Investors use it to understand the true average price paid or received, judge execution quality, and compare trading performance against market movement.

open market or private transaction market

"Sale in open market or private transaction"

FAQ

What insider transaction did KROS director Charles W. Newton report?

Charles W. Newton reported a sale of 551 shares of Keros Therapeutics, Inc. common stock on August 18, 2026, in a transaction coded as a sale in an open market or private transaction.

At what price did the KROS insider shares sell?

The reported weighted average sale price was $10.30 per share. The filing states the shares were sold in multiple transactions at prices ranging from $10.16 to $10.49 per share, inclusive.

How many KROS shares does Charles W. Newton own after this transaction?

After the reported sale, Charles W. Newton directly holds 12,114 shares of Keros Therapeutics, Inc. common stock, according to the Form 4.

Was the KROS insider sale under a Rule 10b5-1 plan?

Yes. The filing states the transactions were made pursuant to a Rule 10b5-1 trading plan adopted by Charles W. Newton on March 12, 2026, and the Rule 10b5-1 checkbox is marked true.

How many KROS shares did the insider sell in total in this filing?

The Form 4 reports that Charles W. Newton sold 551 shares of Keros Therapeutics, Inc. common stock in this transaction, with no additional purchases or derivative exercises reported.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google

Available on EDGAR 08/20/2026 - 04:10 PM Accepted by SEC EDGAR 08/20/2026 - 04:10 PM

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Newton Charles W.

(Last)

(First)

(Middle)

C/O KEROS THERAPEUTICS, INC.

1050 WALTHAM STREET, SUITE 302

(Street)

LEXINGTON

MASSACHUSETTS

02421

(City)

(State)

(Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Keros Therapeutics, Inc. [ KROS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director	10% Owner
	Officer (give title below)	Other (specify below)

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/18/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	Amount	(A) or (D)	Price		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
Common Stock	08/18/2026		S⁽¹⁾		551	D	$10.3⁽²⁾	12,114	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares	8. Price of Derivative Security (Instr. 5)		10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)

Explanation of Responses:

1. The transactions were pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on March 12, 2026.

2. The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $10.16 to $10.49 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

	/s/ Esther Cho, Attorney-in-Fact	08/20/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)

Source: View Original Filing on SEC EDGAR